Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension

[1]  M. Humbert,et al.  Validation of a risk assessment instrument for pulmonary arterial hypertension , 2018, European heart journal.

[2]  J. Barberà,et al.  Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  H. Ghofrani,et al.  Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study , 2018, American Journal of Cardiovascular Drugs.

[4]  M. Humbert,et al.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[5]  S. Rosenkranz,et al.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[6]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[7]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[8]  H. Ghofrani,et al.  Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.

[9]  M. Humbert,et al.  Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension , 2014, Circulation.

[10]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[11]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[12]  R. Tuder,et al.  Pathology of pulmonary hypertension. , 2013, Clinics in chest medicine.

[13]  G. Simonneau,et al.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[14]  R. Tuder,et al.  Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.

[15]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[16]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[17]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.